LIFE

New Medical Life Science | December 19, 2016

The U.S. Food and Drug Administration today granted accelerated approval to Rubraca (rucaparib) to treat women with a certain type of ovarian cancer. Rubraca is approved for women with advanced ovarian cancer who have been treated with two or more chemotherapies and whose tumors have a specific gene mutation (deleterious BRCA) as identified by an FDA-approved companion diagnostic test...

Allergan | December 22, 2016

US-based drugmaker Allergan has signed an agreement to acquire Acelity’s regenerative medicine unit LifeCell in a deal valued at $2.9bn.The acquisition will combine LifeCell's business, including its portfolio of dermal matrix products with Allergan's portfolio of medical aesthetics, breast implants and tissue expanders....

Novartis | December 22, 2016

Novartis has announced the launch of an innovative technology-based healthcare program called SMS for Life 2.0 in Kaduna State, Nigeria. The program aims to increase the availability of essential medicines and improve care for patients across the region by using simple, available, and affordable technology. SMS for Life 2.0 is a joint public-private partnership led by Novartis and supported by its partners, the Kaduna State Ministry of Health and Vodacom...

news medical life science | December 23, 2016

The University of Cambridge and King's College London have jointly developed intellectual property (IP) regarding the underlying cellular mechanisms that cause the calcification (or hardening) of arteries and veins as we age. These biological processes can cause vascular diseases and, through impeding blood flow, can cause heart disease and stroke. The recently licenced IP includes a patent application and know-how relating to the use of PARP inhibitor drugs for the treatment of vascular disease...